Rituximab associated neutropenia: Description of three cases and an insight into the underlying pathogenesis

Alina Weissmann-Brenner, Baruch Brenner, Inessa Belyaeva, Meir Lahav, Esther Rabizadeh

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: To describe Rituximab associated neutropenia (RAN), and to explore its underlying mechanism. Case Report: We describe three patients with RAN. The effect of patient's plasma on colony forming unit, Granulocyte-Monocyte (CFU-GM) was measured by the addition of plasma to the culture of a healthy bone-marrow. Repeated tests were performed after recovery of white count. In the leukopenic period the patient's plasma inhibited CFU growth completely. Control plasma did not have such an effect. Addition of patient's cell supernatant to bone marrow cells did not change the number of CFU. The same effect was demonstrated in normal control. After recovery the patient's plasma did not inhibit colony formation, similar to control. Conclusions: RAN is a clinically significant side effect. It may take place during treatment or several months afterwards. Circulating antibodies in the plasma may be responsible for this unique BM toxicity.

Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalMedical Science Monitor
Volume17
Issue number11
DOIs
StatePublished - Nov 2011
Externally publishedYes

Keywords

  • Bone marrow
  • Neutropenia
  • Pathogenesis
  • Rituximab

Fingerprint

Dive into the research topics of 'Rituximab associated neutropenia: Description of three cases and an insight into the underlying pathogenesis'. Together they form a unique fingerprint.

Cite this